Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition

BACKGROUND: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor load changes during targeted therapy with crizotinib. We explored whether (18)F-FDG PET meas...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:PLoS One
Main Authors: Kerner, Gerald S. M. A., Koole, Michel J. B., Bongaerts, Alphons H. H., Pruim, Jan, Groen, Harry J. M.
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2016
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854442/
https://ncbi.nlm.nih.gov/pubmed/27137772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0149955
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker